Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AtTEnd
2018-001072-37Phase 3Unknown
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of atezolizumab in endometrial cancer (EC), endometrial carcinosarcoma, sponsored by Mario Negri Institute for Pharmacological Research. Status: unknown.
02
Drugs
atezolizumab
03
Conditions
endometrial cancer (EC)endometrial carcinosarcoma
Beyond the preview
Go deeper on 2018-001072-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001072-37.